XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenue | 9 Months Ended
--- | ---
Sep. 30, 2018
Revenue |
Revenue | Note 3 — Revenue Revenue from contracts with customers arises from one customer, which is GSK, in one geographic location, which is the United Kingdom. Revenue comprises the following categories (in thousands):
|  | Three months ended September 30, |  | Nine months ended September 30, |
|  | 2018 |  | 2018 |
Development |  | $ | 1,678 |  | $ | 18,912 |
Licenses |  | 39,114 |  | 39,114 |
|  | $ | 40,792 |  | $ | 58,026 |
The deferred revenue balance as of January 1, 2018 and September 30, 2018 is as follows (in thousands):
|  | September 30, 2018 |  | January 1, 2018 |
Deferred revenue |  | $ | 1,345 |  | $ | 30,090 |
Deferred revenue has decreased from $30,090,000 at January 1, 2018 to $1,345 at September 30, 2018 primarily due to the recognition of license revenue of $39,114,000 for the NY-ESO License which commenced in September 2018, of which $27,001,000 was included in the opening balance of deferred revenue. A further $1,787,000 of the revenue recognized in the nine months ended September 30, 2018 was included in the opening balance of deferred revenue. The impact of changes in variable consideration in the three and nine months ended September 30, 2018 was nil and a reduction in deferred revenue of $10,396,000, respectively, and the impact of changes in the percentage of completion in the three and nine months ended September 30, 2018 was to increase deferred revenue by $45,000 and $5,027,000, respectively. The aggregate amount of the transaction price, excluding variable consideration which is constrained to reduce the consideration to the amount which is probable of being received, allocated to the performance obligations that are unsatisfied (or partially satisfied) as of September 30, 2018 was $1,345,000. This amount comprises $88,000 of revenue allocated to partially satisfied performance obligations for the NY-ESO program and a further $1,257,000 of revenue allocated to the partially satisfied performance obligations for the PRAME program. The NY-ESO program transferred to GSK on July 23, 2018 which resulted in the revenue allocated to the NY-ESO License being recognized in the third quarter of 2018. The revenue allocated to the performance obligations for the NY-ESO program of $88,000 will be recognized over the remainder of 2018. The revenue allocated to the PRAME program of $1,257,000 will be recognized over an estimated development period. As of September 30, 2018, this is estimated to be six months.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration